CalciMedica, Inc. Common Stock (CALC)vsInsmed Inc (INSM)
CALC
CalciMedica, Inc. Common Stock
$0.62
-4.01%
HEALTHCARE · Cap: $9.09M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
CALC leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
CALC
Avoid19
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CALC
The strongest argument for CALC centers on Debt/Equity.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CALC
The primary concerns for CALC are Revenue Growth, EPS Growth, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CALC profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
CALC carries more volatility with a beta of 1.24 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
CALC generates stronger free cash flow (-5M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 19/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CalciMedica, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CalciMedica, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapies for acute and chronic conditions related to calcium-dependent pathways, particularly with its lead candidate, CM4620, aimed at addressing severe muscle cramps in sickle cell disease. The company utilizes a proprietary technology platform to create innovative calcium modulators and has assembled a strong pipeline bolstered by a veteran management team and strategic collaborations to accelerate clinical development. With its dedication to addressing critical unmet medical needs and transforming treatment landscapes, CalciMedica represents a unique and promising investment opportunity within the biopharmaceutical sector.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?